Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

NOVARTIS AG : Barclays reaffirms its Sell rating

11/27/2020 | 07:09am EST

In a research note published by Emily Field, Barclays advises its customers to Sell the stock. The target price is still set at CHF 75.


© MarketScreener with dpa-AFX Analyser 2020
Stocks mentioned in the article
ChangeLast1st jan.
BARCLAYS PLC -2.66% 148.8 Delayed Quote.1.45%
NOVARTIS AG 2.13% 85.3 Delayed Quote.1.97%
All news about NOVARTIS AG
01/15NOVARTIS : Deutsche Bank Starts Novartis at Buy
MT
01/15NOVARTIS AG : Gets a Buy rating from Deutsche Bank
MD
01/15NOVARTIS : Exane BNP Paribas Lowers Price Target on Novartis, Maintains Outperfo..
MT
01/14Invitae to Develop Standardized Panel to Detect Molecular Residual Disease as..
MT
01/14NOVARTIS : Gets FDA Breakthrough-Therapy Designation for Ligelizumab
DJ
01/14NOVARTIS AG : UBS maintains a Buy rating
MD
01/14NOVARTIS' : Ligelizumab Receives FDA Breakthrough Therapy Designation for Urtica..
MT
01/14NOVARTIS : Skin Disease Treatment Ligelizumab Gets US FDA's Breakthrough Therapy..
MT
01/14NOVARTIS : Court Rejects Attempt To "Stretch" Patent Claim Language
AQ
01/14NOVARTIS : ligelizumab (QGE031) receives FDA Breakthrough Therapy designation fo..
PU
More news
Financials (USD)
Sales 2020 49 176 M - -
Net income 2020 8 396 M - -
Net Debt 2020 19 973 M - -
P/E ratio 2020 26,0x
Yield 2020 3,31%
Capitalization 218 B 218 B -
EV / Sales 2020 4,83x
EV / Sales 2021 4,42x
Nbr of Employees 110 000
Free-Float 86,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 109,22 $
Last Close Price 95,66 $
Spread / Highest target 47,2%
Spread / Average Target 14,2%
Spread / Lowest Target -14,1%
EPS Revisions
Managers and Directors
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans JŲrg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG1.97%218 041
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993
ABBVIE INC.3.15%195 120